Pharmaceutical

Rats have an imagination, too, researchers show with brain implants

Rats have an imagination, too, researchers show with br...

Nov 3, 2023

Rats think of objects and places that are not directly in front of them, a key r...

Listen: Decoding biotech hype, the Sarepta saga, & au r...

Nov 3, 2023

This week on "The Readout LOUD" podcast: When is a failure not a failure? Does t...

STAT+: Could kidney transplant patients be spared a lifetime of immunosuppressants?

STAT+: Could kidney transplant patients be spared a lif...

Nov 3, 2023

In a small trial, 63% of kidney transplant patients were able to discontinue imm...

Senate bill would permanently extend Covid-era rules on telehealth addiction treatment

Senate bill would permanently extend Covid-era rules on...

Nov 3, 2023

A bipartisan bill would permanently extend a Covid-era policy that allowed patie...

Camidanlumab tesirine by ADC Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Camidanlumab tesirine by ADC Therapeutics for Myelodysp...

Nov 2, 2023

Camidanlumab tesirine is under clinical development by ADC Therapeutics and curr...

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle Muscular Dystrophy: Likelihood of Approval

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle ...

Nov 2, 2023

AB-1003 is under clinical development by Asklepios BioPharmaceutical and current...

Darovasertib by Ideaya Biosciences for Colorectal Cancer: Likelihood of Approval

Darovasertib by Ideaya Biosciences for Colorectal Cance...

Nov 2, 2023

Darovasertib is under clinical development by Ideaya Biosciences and currently i...

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Likelihood of Approval

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Li...

Nov 2, 2023

GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently ...

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syn...

Nov 2, 2023

APVO-436 is under clinical development by Aptevo Therapeutics and currently in P...

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likelihood of Approval

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likel...

Nov 2, 2023

PRT-811 is under clinical development by Prelude Therapeutics and currently in P...

Bezuclastinib by Cogent Biosciences for Systemic Mastocytosis: Likelihood of Approval

Bezuclastinib by Cogent Biosciences for Systemic Mastoc...

Nov 2, 2023

Bezuclastinib is under clinical development by Cogent Biosciences and currently ...

Rituximab biosimilar by Celltrion for Waldenstrom Macro...

Nov 2, 2023

Rituximab biosimilar is under clinical development by Celltrion and currently in...

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: L...

Nov 2, 2023

Gebasaxturev is under clinical development by Merck and currently in Phase II fo...

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Likelihood of Approval

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Li...

Nov 2, 2023

ALG.APV-527 is under clinical development by Alligator Bioscience and currently ...

New antibiotic targets gonorrhea as well as last existing treatment, study shows

New antibiotic targets gonorrhea as well as last existi...

Nov 1, 2023

An important Phase 3 trial has shown that a new drug that targets gonorrhea work...

STAT+: After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy

STAT+: After Sarepta trial failure, families and doctor...

Nov 1, 2023

Sarepta Therapeutics celebrated the results of a clinical trial of its Duchenne ...